This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mueller, K. L. Articles by Boerner, J. L. Search for Related Content PubMed PubMed Citation Articles by Mueller, K. L. Articles by Boerner, J. L.

Met and c-Src Cooperate to Compensate for Loss of Epidermal Growth Factor Receptor Kinase Activity in Breast Cancer Cells

¹ Karmanos Cancer Institute; Departments of ² Pharmacology and ³ Pathology, Wayne State University, Detroit, Michigan

Requests for reprints: Julie L. Boerner, Department of Pharmacology, Wayne State University/Karmanos Cancer Institute, 816 Hudson Webber Cancer Research Center, 4100 John R. Street, Detroit, MI 48201. Phone: 313-576-8351; Fax: 313-576-8029; E-mail: boernerj{at}karmanos.org.

Key Words: EGFR • c-Src • Met • breast cancer • transphosphorylation

Breast cancers are not responsive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), although 30% of breast cancers overexpress EGFR. The mechanism of intrinsic resistance to EGFR TKIs in breast cancer is the focus of current studies. Here, we observed that EGFR remains tyrosine phosphorylated in breast cancer cells that proliferate in the presence of EGFR TKIs. In one such cell line, SUM229, inhibiting c-Src kinase activity with either a dominant-negative c-Src or a c-Src TKI decreased EGFR phosphorylation on Tyr⁸⁴⁵, Tyr⁹⁹², and Tyr¹⁰⁸⁶ in the presence of EGFR TKIs. Conversely, overexpressing wild-type (wt) c-Src in the EGFR TKI–sensitive breast cancer cell line SUM149 increased EGFR kinase–independent EGFR tyrosine phosphorylation. In addition, in the presence of EGFR TKIs, inhibiting c-Src kinase activity decreased cell growth in SUM229 cells, and overexpressing wt-c-Src increased cell growth in SUM149 cells. We identified the receptor tyrosine kinase Met to be responsible for activating c-Src in SUM229 cells. Inhibiting Met kinase activity with a small molecule inhibitor decreased c-Src phosphorylation and kinase activation. In addition, inhibiting Met kinase activity in SUM229 cells decreased EGFR tyrosine phosphorylation and growth in the presence of EGFR TKIs. Stimulating Met kinase activity in SUM149 cells with hepatocyte growth factor increased EGFR tyrosine phosphorylation and cell growth in the presence of EGFR TKIs. These data suggest a Met/c-Src–mediated signaling pathway as a mediator of EGFR tyrosine phosphorylation and cell growth in the presence of EGFR TKIs. [Cancer Res 2008;68(9):3314–22]

This article has been cited by other articles:

				J. P. Eder, G. F. Vande Woude, S. A. Boerner, and P. M. LoRusso Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer Clin. Cancer Res., April 1, 2009; 15(7): 2207 - 2214. [Abstract] [Full Text] [PDF]